News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,208 Results
Type
Article (13760)
Company Profile (101)
Press Release (251347)
Section
Business (88039)
Career Advice (465)
Deals (15342)
Drug Delivery (67)
Drug Development (36600)
Employer Resources (49)
FDA (6289)
Job Trends (6196)
News (150203)
Policy (14026)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23212)
ALS (36)
Alzheimer's disease (391)
Antibody-drug conjugate (ADC) (37)
Approvals (6326)
Artificial intelligence (102)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (585)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (21)
Cell therapy (85)
Cervical cancer (4)
Clinical research (30877)
Collaboration (325)
Compensation (138)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (118)
Cystic fibrosis (35)
Data (604)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1316)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32075)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37396)
Executive appointments (358)
FDA (6686)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (205)
Gene editing (37)
Generative AI (8)
Gene therapy (99)
GLP-1 (339)
Government (1285)
Grass and pollen (2)
Guidances (15)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (79)
Lymphoma (52)
Machine learning (1)
Management (16)
Manufacturing (142)
MASH (31)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9655)
Metabolic disorders (246)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (563)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (678)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (44)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28874)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8037)
Phase II (13062)
Phase III (11725)
Pipeline (412)
Podcasts (46)
Policy (59)
Postmarket research (1401)
Preclinical (3210)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2633)
Recruiting (17)
Regulatory (10089)
Reports (14)
Research institute (564)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (35)
Series B (12)
Service/supplier (3)
Sickle cell disease (31)
Southern California (693)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (29)
United States (6875)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (46)
Last 7 days (256)
Last 30 days (992)
Last 365 days (12077)
2025 (3059)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20070)
2020 (19037)
2019 (14887)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20090)
Australia (2605)
California (1637)
Canada (872)
China (229)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39373)
Florida (306)
Georgia (36)
Idaho (9)
Illinois (185)
India (14)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1417)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (724)
New Mexico (7)
New York (481)
North Carolina (380)
North Dakota (2)
Northern California (678)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (414)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (693)
Tennessee (34)
Texas (219)
Utah (33)
Virginia (70)
Washington D.C. (29)
Washington State (111)
Wisconsin (14)
265,208 Results for "newron pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
March 11, 2025
·
2 min read
Press Releases
Newron Presents 2024 Financial Results and Provides 2025 Outlook
April 1, 2025
·
18 min read
Pharm Country
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, welcomed investors, analysts and media to its well-attended investor day in New York City.
June 25, 2024
·
10 min read
Pharm Country
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Newron Pharmaceuticals S.p.A. today announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, at Convene, 530 Fifth Avenue (between 44th and 45th Streets) in New York City, from 9:00-11:00 AM EDT.
June 18, 2024
·
7 min read
Pharm Country
Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that it will host its 2024 Investor Day on Tuesday, June 25, 2024, in New York City.
June 5, 2024
·
7 min read
Press Releases
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
January 9, 2025
·
9 min read
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals S.p.A. presented four posters and two oral presentations at the 2024 Annual Congress of the Schizophrenia International Research Society from 3-7 April in Florence, Italy.
April 8, 2024
·
10 min read
Business
Newron Presents 2023 Financial Results and Provides 2024 Outlook
Newron Pharmaceuticals S.p.A. announced its financial results and operational highlights for the business year ended December 31, 2023, and provided an outlook for 2024.
March 19, 2024
·
20 min read
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
Newron Pharmaceuticals S.p.A. presents additional results from the international, randomized, double-blind, placebo-controlled study 008A that evaluated the efficacy and safety of evenamide as add-on treatment in 291 patients not benefitting from their second-generation antipsychotic medication, including clozapine.
May 13, 2024
·
8 min read
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A. reports agreement with the European Investment Bank on an amendment to certain terms of its 2018 financing agreement.
March 15, 2024
·
5 min read
1 of 26,521
Next
